Sugi Predict

Sugi Predict / Compounds / SCHEMBL3485657

SCHEMBL3485657

SCHEMBL3485657

CC(C)(C)c1ccc(C(=O)Cl)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 1/20 0.41
▸ CLK1 P49759 2/20 0.39
▸ CLK2 P49760 2/20 0.39
▸ RAB9A P51151 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ EGFR P00533 2/20 0.36
▸ MLYCD O95822 1/20 0.36
▸ CCR9 P51686 2/20 0.36
▸ DGAT1 O75907 1/20 0.36
▸ P4HA1 P13674 2/20 0.35
▸ P4HTM Q9NXG6 2/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070876 0.82 P4HA1 (0.55) NAPRTALDH1A1SMN1; SMN2MAPTP4HA1
SCHEMBL5366444 0.82 KCNJ1 (0.44) CLK1CLK2RAB9AALDH1A1SMN1; SMN2
SCHEMBL10034527 0.81 CLK1 (0.39) CLK1CLK2RAB9ASMN1; SMN2NPC1
SCHEMBL12775299 0.81 NNMT (0.55) SMN1; SMN2
SCHEMBL30395883 0.81 TRPV4 (0.48) NAPRTMLYCD
SCHEMBL627545 0.81 TRPV4 (0.48) NAPRTMLYCD
Hydrochloric Acid SCHEMBL5125109 0.79 TRPV4 (0.47) NAPRTMLYCD
SCHEMBL22387735 0.78 HDAC6 (0.61) CLK1CLK2
SCHEMBL5527988 0.78 MAPK1 (0.61) RAB9AALDH1A1NPC1MAPTCYP2C19
SCHEMBL12376582 0.78 BAZ2B (0.53) CLK1CLK2RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358929-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2025-07-15 — — US disclosed
US-20240294546-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2024-09-05 — — US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 — — US disclosed
US-11917901-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-02-27 — — US disclosed
EP-3558318-B1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-12-20 — — EP disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
US-11807650-B2 NMDA receptor modulators and uses thereof NOVARTIS AG (CH) 2023-11-07 — — US disclosed
US-20220153755-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2022-05-19 — — US disclosed
US-20220153755-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2022-05-19 — — US disclosed
US-20170170413-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2017-06-15 — — US disclosed
US-20160365520-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2016-12-15 — — US disclosed
US-20160365520-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2016-12-15 — — US disclosed
WO-2015117718-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2015-08-13 — — WO disclosed
WO-2015104045-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2015-07-16 — — WO disclosed
US-20150171348-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-06-18 — — US disclosed
US-20150171348-A1 Metal Complexes MERCK PATENT GMBH (DE) 2015-06-18 — — US disclosed
WO-2014023377-A2 METAL COMPLEXES MERCK PATENT GMBH (DE) 2014-02-13 — — WO disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 — — US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 NAPRT 4035/4885CLK1 2385/4885CLK2 2521/4885
US-11807650-B2 NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C NAPRT 934/4885CLK1 4133/4885CLK2 3434/4885
US-20240294546-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C NAPRT 934/4885CLK1 4133/4885CLK2 3434/4885
US-12358929-B2 NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN2C NAPRT 934/4885CLK1 4133/4885CLK2 3434/4885
US-20150171348-A1 Metal Complexes SOD1, AP1M1, AP3M1 NAPRT 2456/4885CLK1 2647/4885CLK2 2073/4885
US-20160365520-A1 METAL COMPLEXES SOD1, AP1M1, AP3M1 NAPRT 2456/4885CLK1 2647/4885CLK2 2073/4885
US-20170170413-A1 METAL COMPLEXES SOD1, AP1M1, AP3M1 NAPRT 2456/4885CLK1 2647/4885CLK2 2073/4885
US-20220153755-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN2C NAPRT 934/4885CLK1 4133/4885CLK2 3434/4885
US-11917901-B2 Metal complexes MCOLN2, MCOLN1, AP1M1 NAPRT 3541/4885CLK1 2158/4885CLK2 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.